PharmaInternational

Bruton tyrosine kinase inhibitors developed by Roche would apparently be far more effective than those from Sanofi. Indeed, Roche's fenebrutinib met its primary endpoint in a second Phase III study for the treatment of relapsing multiple sclerosis (R